6 Investor presentation First nine months of 2020 Sales growth of 7% driven by Inte Reported geographic sales split for the first nine months of 2020 DKK billion 56 48 40 32 24 16 8 0 Insulin GLP-1 Growth at CER 12% Other diabetes Obesity International Operations 11% 13% 12% IO EMEA China RoW Biopharm 2% NAO 1 ‘Other diabetes’ is included in Total IO: International Operations; EMEA: Europe, Middle East and Africa; China: Mainland China, Hong Kong and Taiwan; RoW: Rest of W Note: Unless otherwise specified, sales growth rates are at CER
Novo Nordisk® ernational Operations and GLP-1 Added reported therapy area sales and growth DKK billion 6 4 2 0 -2 North America Operations International Operations 7% -3% 29% 6% 37% 12% 27% 10% 8% 2% -22% 4% Growth at CER 4% 8% -2% -4 -6 Total1 Insulin GLP-1 Obesity Biopharm World; NAO: North America Operations